Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (Nasdaq: RVMD) generates frequent news as a late-stage clinical oncology company advancing a pipeline of RAS(ON) inhibitors for RAS-addicted cancers. Its public announcements highlight clinical trial milestones, regulatory designations and corporate developments related to drug candidates such as daraxonrasib, elironrasib and zoldonrasib.
News coverage for RVMD often centers on clinical data readouts and trial progress. The company has reported results from studies of daraxonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC) in both previously treated and first-line settings, as well as combination regimens with gemcitabine and nab-paclitaxel. It also releases updates on global Phase 3 trials, including RASolute 302 and 304 in PDAC and RASolve 301 in RAS-mutant non-small cell lung cancer (NSCLC).
Another key news theme is regulatory interaction with the U.S. Food and Drug Administration. Revolution Medicines has announced FDA Breakthrough Therapy Designations for daraxonrasib, elironrasib and zoldonrasib in specific KRAS-mutant NSCLC and pancreatic cancer settings, Orphan Drug Designation for daraxonrasib in pancreatic cancer, and a Commissioner’s National Priority Voucher for daraxonrasib. These items are frequently covered in press releases and investor communications.
Investors and observers can also expect corporate and financial updates, including quarterly financial results, strategic financing transactions such as the Royalty Purchase Agreement with Royalty Pharma, and leadership appointments to support late-stage development and potential commercialization. Conference presentations at major healthcare and oncology meetings, where the company shares updated clinical and preclinical data, are another recurring source of news.
This news page aggregates such disclosures, offering a centralized view of Revolution Medicines’ clinical progress, regulatory milestones and corporate events for those tracking RVMD’s development in RAS-driven oncology.
Revolution Medicines (NASDAQ: RVMD) has announced a public offering of up to $200 million of common stock, with a potential additional $30 million available through underwriters. The offering is subject to market conditions, and completion is not guaranteed. The company focuses on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes RAS(ON) Inhibitors and RAS Companion Inhibitors. The offering aims to fund further development of these therapies.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced the appointment of Lorence Kim, M.D. to its board of directors on July 13, 2022. Dr. Kim, formerly CFO at Moderna, brings vital operational and financial expertise crucial for the company’s development pipeline of targeted therapies for RAS-addicted cancers. He replaces Neil Exter, enhancing the board as clinical trials for RMC-6236 and RMC-6291 progress. The company continues to make strides in evaluating drug combinations, particularly RMC-4630 with sotorasib, showing promising results that may advance cancer treatment.
Revolution Medicines (Nasdaq: RVMD) announced the initiation of patient dosing in its Phase 1/1b clinical trial of RMC-6236, a novel oral RAS(ON) Inhibitor targeting cancers driven by KRAS mutations. This trial represents a significant milestone as RMC-6236 is the first oral, direct RAS inhibitor assessed against tumors with the KRASG12D variant. The study aims to evaluate safety, tolerability, and determine the recommended Phase 2 dose. Additionally, Sushil Patel, Ph.D., has been elected to the board, bringing extensive oncology commercialization experience.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on therapies for RAS-addicted cancers, will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference from June 13-16, 2022. CEO Mark A. Goldsmith will host a live fireside chat on June 15, 2022, at 1:20 p.m. Pacific Time. Investors can access the live webcast at here, with an archived replay available for 14 days post-event.
Revolution Medicines, a clinical-stage oncology company, reported its Q1 2022 financial results, revealing a net loss of $57.6 million, up from $37.2 million in Q1 2021. Total revenue decreased to $7.6 million from $10.2 million year-over-year, mainly due to lower reimbursed development costs with Sanofi. However, the company is advancing its RAS(ON) Inhibitor pipeline, with RMC-6236 and RMC-6291 set to enter clinical trials this year. The company maintains a strong cash position of $518.8 million and expects a full-year net loss of $260 million to $290 million for 2022.
Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the upcoming release of its financial results for Q1 2022 on May 9, 2022, after market close. The senior management team will conduct a conference call and webcast at 4:30 PM ET to discuss these results and update investors on corporate progress. Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers, including a diverse pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors. More details on the call can be found on their investor relations website.
Revolution Medicines (Nasdaq: RVMD) will present its pipeline of RAS(ON) Inhibitors at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The company plans to deliver seven oral presentations, focusing on novel therapies targeting RAS-addicted cancers. Key presentations include insights into RMC-6236, RMC-6291, RMC-9805, and RMC-8839. The company’s innovative tri-complex platform showcases potential first-in-class treatments capable of addressing significant patient needs. Collaborators will also present findings on related therapies.
Revolution Medicines, a clinical-stage oncology company focused on RAS-addicted cancers, announces participation in the Cowen 42nd Annual Health Care Conference. CEO Mark A. Goldsmith will engage in a fireside chat on March 7, 2022, at 11:10 a.m. Pacific. The virtual conference runs from March 7-9, 2022, with a live webcast available on the company’s website. A replay will be accessible for 14 days post-event. Revolution Medicines develops therapies targeting RAS proteins, including RMC-6236 and RMC-4630.
Revolution Medicines (Nasdaq: RVMD) reported financial results for Q4 and full year 2021, with total revenue of $29.4 million, a decline from $43.0 million in 2020. The net loss increased to $187.1 million in 2021 from $108.2 million. The company is advancing its RAS(ON) Inhibitor pipeline, with drug candidates RMC-6236 and RMC-6291 expected to enter clinical trials. New drug candidates RMC-9805 and RMC-8839 have also been nominated. Revolution Medicines anticipates a GAAP net loss of $260 million to $290 million for 2022, including stock-based compensation expenses.
Revolution Medicines, a clinical-stage oncology company, will announce its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call and webcast are scheduled for the same day at 4:30 p.m. Eastern Time to discuss the results and recent corporate developments. Investors can access the live webcast and archived version on the company’s website. Revolution Medicines focuses on developing novel targeted therapies for RAS-addicted cancers, including a range of RAS(ON) Inhibitors and Companion Inhibitors.